鼻咽癌IMRT后MRI检出脑干损伤的演变与剂量学分析
该回顾性研究纳入2009至2015年接受IMRT的6288例鼻咽癌患者,其中24例出现放射性脑干损伤,中位潜伏期14.5个月,37.5%有症状,54.2%完全缓解。最大点剂量是脑干损伤的关键预测因子,最佳等效2Gy分次剂量截断值为67.4 Gy。
要点
- 脑干损伤中位潜伏期14.5个月,37.5%患者有临床症状。
- 最大点剂量是脑干损伤关键预测因子,AUC为0.898。
- Dmax≥67.4 Gy(D2)者脑干损伤风险显著增高(OR=25.29)。
核心结论
- 鼻咽癌IMRT后脑干损伤随时间趋于改善,Dmax=67.4 Gy(D2)可作为脑干剂量约束。
研究设计与样本
- 回顾性分析2009至2015年接受IMRT的6288例鼻咽癌患者,其中24例出现放射性脑干损伤。
- 采用惩罚回归模型识别脑干损伤的关键剂量学预测因子,并用ROC曲线评估性能。
主要发现
- 脑干损伤中位潜伏期14.5个月(范围7.6-37.5个月),24例中9例(37.5%)有临床症状。
- 所有患者均出现水肿性病变和对比增强病变,较大对比增强病变中坏死更常见(P=.007)。
- 中位随访12.5个月后,24例中13例(54.2%)完全缓解,5例(20.8%)部分缓解,缓解与是否给予对症治疗无关。
- Dmax是脑干损伤的关键预测因子(AUC=0.898),最佳D2截断值为67.4 Gy(敏感度=0.833,24例中20例;特异度=0.835,6264例中5234例)。
- Dmax≥67.4 Gy(D2)者发生脑干损伤的风险显著高于Dmax<67.4 Gy(D2)者(OR=25.29;95%CI 8.63-74.14;P<.001)。
关键数值与推荐
- 脑干最大点剂量Dmax=67.4 Gy(D2)为最佳预测截断值,敏感度0.833、特异度0.835。
- Dmax≥67.4 Gy(D2)者脑干损伤风险显著增高(OR=25.29;95%CI 8.63-74.14;P<.001)。
临床怎么用
- 临床可考虑将脑干Dmax约束在67.4 Gy(D2)以下,以平衡靶区覆盖与脑干保护。
- 对脑干损伤患者,无论是否对症治疗,多数病变随时间改善,可密切随访观察。
局限性
- 本研究为回顾性分析,脑干损伤事件数较少(24例),结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the evolution of radiation-induced brain stem injury (BSI) in patients with nasopharyngeal carcinoma (NPC) treated with intensity modulated radiation therapy (IMRT) and to identify the critical dosimetric predictors of BSI. METHODS AND MATERIALS: A total of 6288 NPC patients treated with IMRT between 2009 and 2015 were retrospectively reviewed. Among these 6288 patients, 24 had radiation-induced BSI, which manifested as edematous lesions and contrast-enhanced lesions (CLs) on magnetic resonance imaging. Latency, symptoms, and evolution of BSI were assessed. Critical dosimetric predictors of BSI were identified using a penalized regression model with performance evaluated by receiver operating characteristic curve analysis. RESULTS: Median BSI latency was 14.5 months (range, 7.6-37.5 months), and 9 out of 24 patients (37.5%) were clinically symptomatic. Edematous lesions and CLs were both present in all patients. Necrosis was significantly more common in larger CLs (P = .007). After median follow-up of 12.5 months, 13 out of 24 patients (54.2%) had complete remission, and 5 out of 24 patients (20.8%) had partial remission. Remission was unaffected by whether or not symptomatic treatment was given. Maximum point dose (Dmax) was identified as the critical predictor of BSI (area under the receiver operating curve = 0.898), with the optimal cutoff equivalent dose in 2-Gy fractions (D2) being 67.4 Gy (sensitivity = 0.833, 20 out of 24; specificity = 0.835, 5234 out of 6264). Patients with Dmax ≥67.4 Gy (D2) were significantly more likely to develop BSI (odds ratio = 25.29; 95% CI, 8.63-74.14; P < .001) than those with Dmax <67.4 Gy (D2). CONCLUSIONS: In patients with NPC treated with IMRT, BSI generally tends to improve over time. Dmax = 67.4 Gy (D2) appears to be the dose constraint for brain stem, potentially providing clinicians with greater choice and flexibility when balancing the tumor target coverage and brain stem protection. Further studies are needed to validate our findings.
引用
- Huang XD, Li YC, Chen FP, et al. Evolution and Dosimetric Analysis of Magnetic Resonance Imaging-Detected Brain Stem Injury After Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2019. PMID: 31075310. doi:10.1016/j.ijrobp.2019.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。